Daily Archives: April 1, 2007

YUM – Yum Brands Inc. – Globalization Drives Growth

By Saul Sterman

04/01/2007

Do you recall marketing 101? Here’s a quick recap. Use the ‘cash cow’ to build the ‘rising star’. Not bad, a whole semester in one sentence!

The Yum cash cow is the U.S. operation. Yum expects to eek out 3 to 5 percent earnings growth in the U.S. in 2007. The real story is using the generated cash to grow aggressively overseas. That’s good news because the U.S. is in the midst of a slowdown while Asia is still growing at a fast clip.

Read More »

XEL – Xcel Energy Inc.: Shocking High P/E

By CrossProfit

04/01/2007

In 2006 utility M&A activity started in February with Keyspan Corp (KSE) being acquired by National Grid (NGG) @$41.50 cash. We anticipated this move and expected final regulatory approval to be slow in coming to fruition. What ensued for the remainder of the year was more in line with wishful thinking than reality. A number of acquisitions were announced only to be terminated in the beginning of 2007. Nonetheless, Utilities have continued to trade at above normal multiples.

Read More »

YHOO – Yahoo! Inc: Panama, Passage to Better Earnings

By CrossProfit

04/01/2007

Though Yahoo! is not a verb it is definitely a household word. There is no question that Yahoo! was asleep at the helm allowing the social networking and online video trends to cruise by.

Yahoo! is still number one in display advertising revenue. Yahoo! holds second place after Google in online search yet is ahead of MSFT, TWX and IACI. Panama should increase revenue in both display and search categories. We don’t think that Panama is meant to restore search click status and essentially Yahoo! is content with second place in this category. Panama’s market penetration will be assessed in Q4 2007. By then we will know if Yahoo! has succeeded in reversing the decline in margins and earnings as well.

Read More »

AT&T Goes After International Domination

AT&T (T) and American Movi (AMX)l are offering almost $3.5 billion to take over two-thirds of the holding company that controls Italy’s largest phone company, Telecom Italia (TI).

AT&T is doing the smart thing. Its cell phone business in the US has been a major growth engine, but wireless handset penetration is high and price cutting is almost the only way to pick up market shares. Cable company’s have a much larger beach head in the TV business and can offer most of their customers the dreaded triple play of voice, TV, and broadband service. Dislodging cable from its position with consumers will be expensive, and may not work at all.

AT&T ’s stock is up almost 70% over the last two years, far out-pacing the shares of rival Verizon (VZ). With slower growth just over the horizon in the US, picking up telecom companies overseas makes sense. All the better to squeezed telecom equipment vendors for better prices.

Buying the Italian phone company may be enough to keep Wall St. interesting in AT&T for a little while longer.

Douglas A. McIntyre can be reached at douglasamcintyre@247wallst.com. He does not own securities in companies that he writes about.

Daimler: Beggars Can’t Be Choosers

Late word from Germany is that DaimlerChrysler (DCX) will not let just anyone buy its Chrysler auto unit. The Wall Street Journal speculates that Daimler management will want to share technology with its US unit in the event that a sale goes through. He needs the new buyer’s cooperation.

That probably isn’t the real reason. Daimler chief Dieter Zetsche has a bunch of labor members on his supervisory board. They think, and are almost certainly correct, that if a private equity operation like Cerberus Capital Management or Blackstone Group gets its hands on the company, they will break it into pieces. They might even close units that don’t make money.

Canadian car parts company, Magna International, is also considered a likely bidder. But, since it gets business from Ford (F) and GM (GM), it is very difficult to see how it could own Chrysler without conflicts of interest.

The dark horse among potential bidders still has to be GM. If it can cut a proper deal with the UAW to take some workers out of a merged company, the economies of scale would work in its favor. It would be, once again, the largest car company in the world, by far. GM could certainly share technology with Daimler, which would become a producer of high-end cars and trucks.

GM management says that it is more important to them to be profitable than to be bigger than Toyota (TM). But, the GM board has to know at some level that if the company keeps getting smaller, it will be neither.

Douglas A. McIntyre can be reached at douglasamcintyre@247wallst.com. He does not own securities in companies that he writes about.

EGL: Private Equity Madness

By Ryan Barnes of 24/7 Wall St.

Second Institutional Holder of EGL Questions Buyout Motive

Federated Kauffman filed suit against EGL Inc. (EAGL) on behalf of their Small Cap Fund this weekend, the second large shareholder to publicly denounce the management-led buyout, spearheaded by CEO James Crane along with private equity groups Centerbridge Partners LP and Woodbridge Company.

Crane announced on March 19 that he and his backers would take the company private at $38 per share.  This was after he had already presented the board with another $38/share offer with General Atlantic as his backer; that deal subsequently was taken off the table after an earnings warning on February 7th sent the parties away from the table. 

News of Federated’s suit comes after Ramius Capital sent a public letter to EGL’s board on March 21st questioning the timing of the new offer from Crane, considering that the Apollo Management group was known to be putting a separate private equity offer together for EGL.  The Ramius letter contends that EGL management violated their fiduciary duty by rushing the re-vamped Crane pass the board before allowing Apollo to submit a bid with the proper due diligence.  The letter even contends that the board stonewalled Apollo’s attempts to get records to

Making matters worse is the fact that the CFO resigned a few weeks ago, before the resubmitted buyout offer became public. 

Making things downright ugly are the provisions in the management-led bid that call for a $30 million windfall termination fee to be paid to Crane in the event that another offer is accepted, as well as $15 million in “transaction expenses”. 

Somebody should bring Crane a calculator and help him realize that since he owns just under 18% of the outstanding shares, an offer with a 10% premium to his own $38 bid would be worth over $28 million to Crane personally.

EGL stated that a goal in going private was to “keep our senior management team intact”, shareholders must be asking why that is in any way important, as the company has lagged behind its index for some time.

You can almost hear the professor at Wharton starting his lecture next fall…”Today’s lesson is about how to NOT go about privatizing your company.  One of the best examples we have is that of EGL group, which this spring tried to sidestep the market to protect a few jobs.”

Main competitor UTI Worldwide (UTIW) suffered a mass exodus in its stock on Thursday, when an earnings report filled with margin pressure sent shares down 20%.  The company had been getting a premium valuation up to that point, and the company now trades at a similar valuation to EGL

GM: More Motor City Madness

General Motors (GM) has problems in the big pick-up end of its business and is looking at producing a minicar a the other end.

According to Reuters, GM (GM) and Ford (F) may both have double-digit losses in sales when they report March because everything from slow construction to high gas prices is eating into pick-up purchases. Even problems in sub-prime lending are causing more caution at banks, some of which are raising car loan rates.

The news is especially bad because pick-ups are among the most profitable products Detroit has.

While Ford is hanging onto Jaguar and other under-performing units, GM is at least working on designing more fuel efficient cars.

According to The Wall Street Journal, GM may introduce a minicar in the US. The vehicle would get 50 mpg. The BMW MiniCooper does well in the US, and sales of tiny cars may well improve if gas prices spike over $3 and stay there.

Detroit is not getting any breaks, so it will need to make more of its own. Toyota (TM) has come after the big pick-up truck market with its new Tundra, but its is offering incentives of $3,000 to get drivers into the vehicles. That may force the Big Three to drop prices on their pick-ups. It’s not a good cycle.

The US car companies have not come up with any authentic plan to get investors back in their stocks other than to say that they will "make better cars". That does not seem to resonate when their sales keep dropping so quickly.

Douglas A. McIntyre can be reached at douglasamcintyre@247wallst.com. He does not own securities in companies that he writes about.

Barron’s Alzheimer’s Article Only Scratches the Surface

Stock Tickers: WYE, NRMX, ELN, NVS, PFE, LLY, JNJ, AZN, TRGT, SNH, SRZ, BKD, ALC, HCR, ESC, MYGN, FRX, NYMX, ICGN, MEMY, EPIX, SI, ESALY, MRK, MATK

This weekend, Barron’s has run its cover story on which companies may stand to win in the medical war against Alzheimer’s Disease.  This really only scratches the surface of this devastating problem,even though it is addressing the pipelines that may yield newtreatments.  Barron’s notes drugs that may be able to treat the disease rather than just the symptoms in the next two years.  The article still does a good job to point out the current treatments and some of the companies that have studies that have either completed or being close to completion.   

Wyeth (WYE-NYSE) was the one noted as the best investment bet in the cover story article from Barron’s, which also was noted at the biggest discount to peers. Barron’s also notes: Neurochem (NRMX-NASDAQ) out of Canada, Elan (ELN-NYSE/ADR) in Ireland (and US) (with mixed results in recent years), Novartis (NVS-NYSE/ADR) is Switzerland (And US and elsewhere), Pfizer (PFE-NYSE), Forest Labs (FRX), Eli Lilly (LLY-NYSE), Johnson & Johnson (JNJ-NYSE) were all noted with currently "on the market" drugs in the ongoing studies for possible Alzheimer’s treatments in some form or fashion.  The current drugs from J&J, Novartis, Forest and Pfizer are really meant more as slowing-agents rather than cures.  Unfortunately, there is no magic pill that just zaps this disease.

Neurochem (NRMX) mentioned in the Barron’s article is in Phase III studies in Europe and recently completed Phase III’s in North America for its Alzhemed(TM). It has already filed to raise $102 million in aggregate securities and its balance sheet indicates it may need more cash again at some point in the near future.  This one is perhaps one of the more leveraged names in the article.

Myriad Genetics (MYGN-NYSE) has just completed enrollment ofpatients in its global Phase 3 clinical trial of Flurizan(TM) inAlzheimer’s disease, the first in a new class of drugs known asSelective Amyloid Lowering Agents (SALAs).  This was also noted briefly in the Barron’s article, but these results look promising so far even though the interim results are not planned and results will be unknown until next year.

Forest Lab’s (FRX-NYSE) fiscal March 2006 saw $505 million of $2.96Billion total sales come from Namenda (R) (not Manenda), which was approved in 2003 asan Alzheimer’s treatment.

AstraZeneca (AZN-NYSE) and Targacept (TRGT-NASDAQ) are in Phase II’s for AZD3480 to stimulate the brain’s memory neurotransmitters.

BUT…..there are many more companies here that need to be given some attention.  This is a huge field and there are many mid-cap and small-cap stocks that can be huge beneficiaries of this.  As we have said the Barron’s article is incomplete, and the same will obviously be true here because there are so many aspects to the story.

Our own Douglas McIntyre pointed out several nursing home and assisted care facility operators just on March 20, 2007 after the Wall Street Journal ran an article about the boomers reaching retirement age and the long-term forecasts in the dementia epidemic.  The facilities Doug noted there were Senior Housing (SNH-NYSE) (a REIT), Sunrise Senior Living (SRZ-NYSE), Brookdale Senior Living (BKD), Assisted Living (ALC-NYSE), and Manor Care (HCR).   There are many, many others worth note that have the potential to benefit from this.

Emeritus Corporations (ESC-AMEX) is a national provider of assisted living and Alzheimer’s and related dementia care services to senior citizens.  After the acquisition of Summerville Senior Living announced this last week it will operate 284 communities in 36 states comprising 24,448 units with a capacity for over 28,000 residents. Summerville is adding 81 communities comprising 7,935 units in 13 states which provide independent living, assisted living, and Alzheimer’s and dementia related services to seniors.  This one is more of a pure-play in the assisted living sector, but keep in mind that its stock ran up on this acquisition and its earnings has been spotty.

Nymox Pharmaceutical Corporation’s (NYMX-NASDAQ) in Canada holds some patent rights for statin use for the treatment and prevention of Alzheimer’s disease, so some of these larger statin makers could theoretically end up shelling out some royalties down the road.  Will they really?  Who knows, that’s a long-term issue. 

Icagen, Inc. (ICGN-NASDAQ) has potential candidates as lead compounds for dementia, including Alzheimer’s disease, for which the Company’s collaborator Astellas Pharma Inc. is conducting preclinical studies, and lead compounds for attention deficit/hyperactivity disorder, which were derived from the collaboration and for which the Company is conducting preclinical studies.

Memory Pharmaceuticals (MEMY-NASDAQ) just raised cash ($10M) to help fund its pipeline studies.  These conditions include Alzheimer’s disease, schizophrenia, bipolar disorder and depression.  This one recently saw its stock implode when its MEM1003 failed to show its effectiveness in acute mania in bipolar disorder, and this MEM1003 is actually being studied for Alzheimer’s.  We noted this at the time, so they better hope for better luck there on the new indication.

EPIX Pharmaceuticals (EPIX-NASDAQ) has a compound PRX-03140 which is in a Phase IIa clinical trial in Alzheimer’s disease.  Siemens (SI-NYSE/ADR) an agreement with Wyeth Pharmaceuticals to utilize Siemens’ new research imaging agent in Wyeth’s clinical studies of new therapies in development for Alzheimer’s disease.

 

Eisai Co. Ltd (ESALY-NASDAQ/OTC) has increased its research facilities in the US and is studying E2012 in preliminary Phase I of its gamma secretase modulator that is being evaluated as a potential new treatment for Alzheimer’s disease.  Merck (MRK-NYSE) and Martek Biosciences (MATK-NASDAQ) are each studying seperate tests (not related to each other).

Even in 2000, the Biotechnology Industry Organization estimated that in the United States alone the total cost of Alzheimer’s Disease was approximately $100 Billion per year.  Healthcare costs haven’t been static by any means, so you can take that number on up drastically from there.  After getting to witness on multiple personal occasions the devastationAlzheimer’s and Dementia causes to the patient, their finances, and theimpacts it has on immediate family, this is a topic of personalimportance and interest.  I have added on to the article because thisis a far reaching issue where it doesn’t really seem like one miraclealone is going to be a true cure that eradicates what is by no meansshort of an epidemic as we live longer and longer.  It is estimatedthat 5 million people in the United States alone are living withAlzheimer’s Disease.

Jon C. Ogg
March 31, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.